Opinion|Videos|April 18, 2025
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Panelists discuss how medical professionals anticipate new IL-17 inhibitor data, particularly from head-to-head trials like BE BOLD. Interest is growing in sonelokimab, an IL-17A/F nanobody (Papp, 2021). Further research is needed on long-term efficacy, safety, and optimal patient selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What new data are you looking forward to seeing from the IL-17 inhibitor class in psoriasis?
- More head-to-head studies (BE BOLD)
- Sonelokimab—IL-17A/F nanobody (Papp, 2021)
- In your opinion, what research still needs to be done for this therapeutic class?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
